9 › 9.1
9.1 Arrhythmias and conduction disturbances
Pages 58–60 · open in PDF
Recommendations in this section
- Class ILevel AOral anticoagulation is recommended in patients with clinical AF at elevated thromboembolic risk, as determined by CHA₂DS₂-VA score, to prevent ischaemic stroke and thromboembolism.
- Class ILevel B1DOACs are recommended in preference to VKAs in patients with HF to prevent stroke and thromboembolism.
- Class ILevel CBeta-blockers are recommended in stable patients with HFrEF and AF as first-line therapy for short- and long-term rate control.
- Class IIaLevel CDigoxin should be considered in stable patients with HFrEF and AF when the ventricular rate remains high despite beta-blockers, or when beta-blockers are contraindicated/not tolerated, in order to obtain short- and long-term rate control.
- Class IIaLevel B1Atrioventricular node ablation combined with CRT should be considered in patients with severely symptomatic permanent AF and poor rate control despite medical therapy and at least one HFH to reduce symptoms, physical limitations, recurrent HFH, and death.
- Class IIbLevel CIntravenous amiodarone or digoxin may be considered in haemodynamically unstable patients with HFrEF and AF to stabilize the patient and achieve acute control of heart rate.
- Class ILevel CUrgent cardioversion is recommended in the setting of DHF in patients presenting with rapid ventricular rates and haemodynamic instability to restore sinus rhythm.
- Class IIaLevel CCatheter ablation for AF should be considered in selected patients with symptomatic AF and HFrEF to improve QoL and reduce the risk of HFH or death.
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 58 · PDF
8.2.4. Symptom control and end-of-life care
Table 17 Indications and contraindications for heart transplantation
Advanced HF and no other therapeutic option (except for durable MCS as BTT) Absolute contraindications Inability to comply with the therapeutic regimen (e.g. dementia) Serious comorbidities with poor prognosis, not reversible with heart transplantation Other contraindications Active infectionb Severe peripheral arterial or cerebrovascular disease Elevated pulmonary vascular resistance (if pharmacologically irreversible)c Cancerd Irreversible liver dysfunction (cirrhosis) or irreversible kidney dysfunctione Systemic disease with multiorgan involvement BMI >35 kg/m2 or severe cachexia
Alcohol or substance abuse or active smoking within the past 6 months Psychological instability Insufficient social support to achieve compliant care in the outpatient setting
Eligibility for each option may change according to the specific conditions of each patient, which may also change over time. Some younger patients prefer to remain on LVAD for a prolonged period, rather than proceeding to transplantation immediately, to increase the potential number of life years gained. Other factors not related to the patient, such as average time on the heart transplantation waiting list, the centre’s surgical experience, and resources, can also influence decision-making.
Precipitating factors for AF – e.g. hyperthyroidism, toxic agents (e.g. including alcohol), valvular heart diseases, infection, diabetes, uncontrolled hypertension, obesity, sleep disorders, and volume overload – should be routinely identified and appropriately managed. Diuretic therapy is indicated to relieve congestion and may increase the chances of restoring sinus rhythm by reducing filling pressures and ventricular rate.
to FMT and GDIT, and without contraindications, to improve QoL and 622,626
FMT, foundational medical therapy; GDIT, guideline-directed interventional therapy; HF, heart failure; QoL, quality of life. a Class of recommendation. b Level of evidence. c Eligibility criteria are reported in Table 17.
Heart transplantation is recommended in selectedc patients with advanced HF refractory
9.1.1. Atrial fibrillation
9.1.1.1. Identification of triggers and risk factor management
Recommendation Table 14 — Recommendations for heart transplantation (see Evidence Tables 75 and 76) Classa
9.1. Arrhythmias and conduction disturbances Heart failure and AF frequently coexist, with AF occurring in more than half of patients with HF, and HF occurring in more than one-third of patients with AF. The prevalence of AF is slightly higher in patients with HFpEF compared with HFrEF.195,628–631 The two conditions are deeply interrelated with shared risk factors and pathophysiological mechanisms. The coexistence of HF and AF is associated with a high risk of death, HFH, and stroke regardless of LVEF.195,628–631 HF induced by AF appears to have a more favourable outcome than HF causing AF.13,632 The management of patients with HF and AF include identification of triggers, prevention of embolic events, management of HF, and rate or rhythm control of AF.
BMI, body mass index; BTT, bridge to transplantation; CPET, cardiopulmonary exercise testing; HF, heart failure; LVAD, left ventricular assist device; MCS, mechanical circulatory support; RHC, right heart catheterization. a Indication by heart transplantation centre includes assessment of HF severity by RHC and/or CPET. b Active infection is a relative contraindication to transplantation, but infected LVAD may be an indication. c LVAD as bridge to candidacy should be considered. d Highly selected cases may be eligible, to be discussed with an oncologist. e Combined heart–liver or heart–kidney transplantation may be considered.
9. Cardiovascular comorbidities
9.1.1.2. Prevention of embolic events Oral anticoagulation is recommended in patients with HF and AF to reduce the risk of thromboembolism, according to the CHA2DS2-VA score (Table 18).118,633–635 However, patients with HCM and CA are at higher risk of thromboembolism irrespective of CHA2DS2-VA score, and anticoagulation is recommended for all these patients with AF.636–642 In the absence of mechanical prosthetic heart valves and/or moderate
Advance care planning is recommended in parallel to advanced HF treatments to determine goals of care and improve QoL along the disease trajectory.627 For indications and the core components of end-of-life care, see Supplementary data online, Table S20. End-of-life care in advanced HF focuses on symptom management (including breathlessness, pain, and anxiety and depression), patient comfort, and maintaining QoL ensuring personalized, compassionate care. It involves clear communication, shared decisionmaking, and integrating palliative or hospice care to support both the patient and their family. For further details on symptom management, see Supplementary data online, Section S5.2.3. Patients on durable MCS may request withdrawal of lifesustaining treatments because these are no longer consistent with their goals of care, because of poor QoL or newly developed serious comorbidities such as cancer. The MCS may be deactivated after careful evaluation of the patient’s wish and by, or under the supervision of, a specialized team. This decision has to take national laws into account. For details regarding follow-up in patients with advanced HF see section 11.6.2 and Recommendation Table 26.
Page 59 · PDF
Updated definitions for the CHA2DS2-VA score Description
Stroke/transient ischaemic attack/arterial
Vascular disease (CAD and/or PAD)
CAD, coronary artery disease; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65– 74 years; PAD, peripheral artery disease. A CHA2DS2-VA score of 2 or more is recommended as an indicator of elevated thromboembolic risk for decisions on initiating oral anticoagulation. A CHA2DS2-VA score of 1 should be considered an indicator of elevated thromboembolic risk for decisions on initiating oral anticoagulation.
or severe mitral stenosis, direct-acting oral anticoagulants are recommended as the anticoagulant of choice.643–646 Left atrial appendage closure can be an option for selected patients as described in the 2024 ESC Guidelines for the management of atrial fibrillation.118,647–651
9.1.1.3. Management of heart failure and atrial fibrillation All patients with coexisting HF and AF should be optimally treated with FMT, AMT, and GDIT regardless of AF (Section 6.2.4).435 In patients with AF and HFrEF, where there may be a high likelihood of LVEF recovery following rhythm control, evidence remains limited. However, given the well-established prognostic benefit of FMT on long-term prognosis in the general HFrEF population, initiation of FMT upfront seems reasonable. There is ongoing debate regarding the optimal management of AF in patients with HF. Currently, there is insufficient evidence to support a rhythm-control strategy over a rate-control strategy.337,652–658 Decisions with regard to choice of strategy must be made taking into account the cause–effect relationship between AF and HF, along with clinical presentation, symptom burden, stage of disease, comorbidities, and patient preference.
9.1.1.4. Rate control Data to support strict vs lenient rate control in patients with HF and AF are inconclusive. Analyses from a large observational registry showed a significant association between heart rate in AF and long-term death only in patients with HFrEF and heart rate >100 b.p.m.659,660 The RACE II trial demonstrated that lenient rate control (target heart rate <110 b.p.m.) was non-inferior to strict rate control (<80 b.p.m. at rest; <110 b.p.m. during exercise) in patients with permanent AF with a primary endpoint of death from CV causes, HFH, stroke, systemic embolism, bleeding, and life-threatening arrhythmic events.307 A post-hoc combined analysis from the AFFIRM and the RACE trials showed similar results.661 However, these trials were not focused on HF and only a minority of patients included had HF. A large observational study showed that a lenient rate-control strategy and poor rate control are associated with a higher risk
of death as compared with strict rate control in patients with AF and HF regardless of LVEF.662 Lenient rate control, with resting heart rate <110 b.p.m., should be considered as initial target in both patients with and without HF, with re-evaluation based on symptoms.118 Beta-blockers have proven safety and efficacy in patients with AF and HFrEF and are recommended as the first-line approach.663,664 If the ventricular rate control is suboptimal with beta-blockers, or if beta-blockers are not tolerated, digoxin or digitoxin should be considered.665–667 In patients with HFrEF who are haemodynamically unstable, i.v. amiodarone or digoxin may be used to achieve acute control of heart rate and improve haemodynamics, although acute electrical cardioversion to restore sinus rhythm should be first choice.668–671 There is no evidence on pharmacological strategies for rate control in patients with AF and HFpEF. Atrioventricular node ablation combined with CRT was found to be superior to pharmacological therapy in reducing death and HFH and improving QoL in patients with severely symptomatic permanent AF and HF, regardless of LVEF.672,673
9.1.1.5. Rhythm control The results of RCTs comparing catheter ablation vs pharmacological rhythm control in patients with HFrEF cannot be considered conclusive for hard outcomes on HFH and death, although catheter ablation has proven superior to antiarrhythmic treatment for AF recurrence.674–682 Data on the role of catheter ablation in HFpEF are limited.683,684 For a detailed description, see Supplementary data online, Section S6.1.1.674–681,683–686 Based on current evidence, catheter ablation should be considered only in carefully selected patients with HFrEF and symptomatic AF. This Task Force suggests that these criteria should be used to guide the selection of patients for catheter ablation: high burden AF,687 less than 1-year duration of continuous persistent AF, and a clear cause–effect relationship between AF and HF. In patients presenting with DHF, AF with rapid ventricular rates, and haemodynamic instability, urgent cardioversion is recommended. Pharmacological and electrical cardioversion seem to have similar outcomes, although specific studies in HF populations are lacking.688,689 Amiodarone is recommended in patients with HFrEF requiring pharmacological cardioversion. Other antiarrhythmic drugs, i.e. propafenone, flecainide, and dronedarone, are associated with poorer outcomes in HFrEF and should be avoided.690–694 There are no data on pharmacological cardioversion in HFpEF. Recommendation Table 15 — Recommendations for management of atrial fibrillation in patients with heart failure (see Evidence Tables 77–81) Recommendations
Recommendations for anticoagulation Oral anticoagulation is recommended in patients with clinical AF at elevated thromboembolic risk, as determined by CHA2DS2-VA scorec, to prevent ischaemic stroke and thromboembolism.635 Continued
Page 60 · PDF
VKAs in patients with HFd to prevent stroke and
thromboembolism. Rate control
Beta-blockers are recommended in stable patients with HFrEF and AF as first-line therapy for short- and long-term rate control.663,665 Digoxin should be considered in stable patients with HFrEF and AF when the ventricular rate remains high despite beta-blockers, or when beta-blockers are contraindicated/not
tolerated, in order to obtain short- and long-term rate control.665–667
Pacing indications in patients with HF do not differ from those without HF. However, long-term RV pacing can adversely impact LV function.706 In patients with HFrEF, where there is an expectation of high pacing requirements, i.e. complete heart block or AF with slow ventricular response, CRT implantation should be considered to improve outcomes (see Recommendation Table 7).409
Atrioventricular node ablation combined with CRT should be considered in patients with severely symptomatic permanent AF and poor rate control despite medical therapy and at least one HFH to reduce symptoms, physical
limitations, recurrent HFH, and death.672,673 Intravenous amiodarone or digoxin may be
9.2. Chronic coronary syndromes
considered in haemodynamically unstable patients with HFrEF and AF to stabilize the patient and achieve acute control of heart
Obstructive CAD is a frequent cause of HF.33 Coronary microvascular dysfunction affects up to 80% of patients with HFpEF and seems to be associated with poor prognosis.707–709 Diagnostic work-up of chronic coronary syndromes in patients with HF is described in Section 5. Treatment of chronic coronary syndrom in patients with established HF is described below.
rate.668–671 Cardioversion Urgent cardioversion is recommended in the setting of DHF in patients presenting with rapid ventricular rates and haemodynamic instability to restore sinus rhythm.669,671,692,695
Catheter ablation for AF should be considered in selectede patients with symptomatic AF and HFrEF to improve QoL and reduce the risk
of HFH or death.674–676,678,681,682,684,696 AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/ arterial thromboembolism (2 points), vascular disease, age 65–74 years; CRT, cardiac resynchronization therapy; DHF, decompensated heart failure; DOAC, direct-acting oral anticoagulant; HF, heart failure; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ejection fraction; QoL, quality of life; VKA, vitamin K antagonist. a Class of recommendation. b Level of evidence. c See Table 18. d Except for patients with moderate or severe mitral stenosis and in patents with mechanical prosthetic heart valves where VKAs are recommended. e All the following criteria are required: high burden AF, less than 1-year duration for continuous persistent AF, clear cause–effect relationship between AF and HF.
9.1.2. Ventricular arrhythmias Ventricular arrhythmias may cause HF or be a consequence thereof. In sustained ventricular tachycardia, initial management should include stabilization (electrical cardioversion), followed by identification and correction of precipitating factors, and optimization of FMT. Although amiodarone reduces ventricular arrhythmias, it does not reduce SCD or death.697 Patients with HF and resuscitated cardiac arrest or life-threatening ventricular arrhythmias have an indication for a secondary prevention ICD.119
Atrial fibrillation catheter ablation
Beta-blockers are recommended as first-line therapy in patients with HFrEF and CAD due to their prognostic effects, closely followed by other FMT drugs.288,290,291,710–712 Ivabradine should be considered in patients with HFrEF in sinus rhythm with heart rate >70 b.p.m. despite beta-blockers at the highest tolerated dose or if beta-blockers are contraindicated.294,713 Other medications such as amlodipine,714 felodipine,715 nicorandil,716 and ranolazine717 do not have effects on death but may improve symptoms. Trimetazidine may improve LV function and exercise capacity in patients with HFrEF and chronic coronary syndrome already on beta-blockers.718–720 Importantly, initiation and/or uptitration of antianginal therapy should not lead to reduction in FMT. Short-acting nitrates can cause hypotension and should be used with caution. Non-dihydropyridine calcium channel blockers (verapamil and diltiazem) are not recommended in patients with HFrEF due to their negative inotropic effects which may precipitate the risk of HF events.721 The use of beta-blockers or calcium channel blockers do not appear to be associated with worse outcomes in HFpEF.722,723 Treatment of patients with HFpEF should be similar to that of patients without HF (see the 2024 ESC Guidelines for the management of chronic coronary syndromes).10
9.2.2. Myocardial revascularization Data to support the prognostic benefit of myocardial revascularization in patients with stable obstructive CAD and HF are limited. Two RCTs compared revascularization vs medical therapy in patients with LVEF ≤35% and multivessel coronary disease.178–180 The STICH trial compared coronary artery bypass grafting (CABG) to medical therapy and showed survival benefit
Heart failure can occur because of frequent PVCs.698 A burden of PVCs of about 10% precipitates an increased risk of HF and the risk increases with higher burden.119,699–701 Thus, regular assessment of LVEF in this setting is indicated. Amiodarone may be considered to reduce recurrent arrhythmias and improve LV function,697 with regular follow-up to assess possible side effects. Catheter ablation of PVCs may improve LV function and, possibly, outcomes in patients with PVCs.702–705 For further details, please refer to the 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.119
DOACs are recommended in preference to